Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
UCB Pharma
ClinicalTrials.gov Identifier:
NCT00113971
First received: June 10, 2005
Last updated: March 30, 2012
Last verified: March 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2007
  Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)